Can kynurenine pathway tryptophan metabolites be used to monitor cadmium exposure?

Polish Journal of Environmental Studies

Volumn 14, Issue 2, 2005, Pages 209-215

  Pawlak, D ^a   Brzoska M ^a   Zwierz, K ^a   Stypulkowska A ^a   Moniuszko Jakoniuk, J ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Cadmium; Kynurenic acid; Kynurenine; N acetyl D glucosaminidase; Rats

Indexed keywords

EID: 14944384711     PISSN: 12301485     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. HAC E., KRZYZANOWSKI M., KRECHNIAK J. Cadmium content in human kidney and hair in the Gdansk region. Sci. Total Environ. 224, 81, 1998.
2. ROELS H. A., HOET P., LISON, D. Usefulness of biomarkers of exposure to inorganic mercury, lead, or cadmium in controlling occupational and environmental risk of nephrotoxicity. Renal Fail. 21, 251, 1999
3. MITSUMORI K., SHIBUTANI M., SATO S., ONODERA H., NAKAGAWA J., HAYASHI Y., ANDO M. Relationship between the development of hepato-renal toxicity and cadmium accumulation in rats given minimum to large amounts of cadmium chloride in the long-term: preliminary study. Arch. Toxicol. 72, 545, 1998.
4. PRICE R. C., PATEL S., CHIVERS I., MILLIGAN P., TAYLOR S. A. Early markers of nephrotoxicity: detection of children at risk from environmental pollution. Renal Fail. 21, 303, 1999.
5. MONIUSZKO-JAKONIUK J., PAWLAK D., BRZÓSKA M. M. Exposure to cadmium and tryptophan metabolism. Toxicol. Lett 123, 48, 2001.
6. PAWLAK D., TANKIEWICZ A., BUCZKO W. Kynurenine and its metabolites in the rat with exerimental renal insufficiency. J. Physiol. Pharmacol. 52, 755, 2001.
7. PAWLAK D., PAWLAK K., MAŁYSZKO J., MYŚLIWIEC M., BUCZKO W. Accumulation of toxic products degradation of kynurenine in hemodialyzed patients. Int. Urol. Nephrol. 33, 399, 2001.
8. PAWLAK D., TANKIEWICZ A., MYSLIWIEC M., BUCZKO W. Tryptophan metabolism via the kynurenine pathway in experimental chronic renal failure. Nephron 90, 328, 2002.
9. PAWLAK D., KODA M., PAWLAK S., WOŁCZYŃSKI S., BUCZKO W. Contribution of quinolinic acid in the development of anemia in renal insufficiency. Am. J. Physiol. 284, F693, 2003.
10. HOLMES E. W., KAHN S. T. Tryptophan distribution and metabolism in experimental chronic renal insufficiency. Exp. Mol. Pathol. 46, 89, 1987.
11. MARTINSONS A., RUDZITE V., GROMA V., BRATASLAVSKA O., WIDNER B., FUCHS D. Kynurenine and neopterin in chronic glomerulonephritis. Adv. Exp. Med. Biol. 467, 579, 1999.
12. SAITO K., FUJIGAKI S., HEYES M. P., SHIBATA K., TAKEMURA M., FUJII H., WADA H., NOMA A., SEISHIMA M. Mechanism of increases in L-kynurenine and quinolinic acid in renal insufficiency. Am. J. Physiol. Renal Physiol. 279, F565, 2000.
13. BUCHI R., ALBERATI-GANI D., MALHERBE P., KOHLER C., BROGER C., CESURA A. M. Cloning and functional expression of a soluble form of kynurenine/ α-aminoadipate aminotransferase from rat kidney. J. Biol. Chem. 270, 29330, 1995.
14. COSTA C. V., RAGAZZI E., CAPARROTTA L., BERTAZZO A., ALLEGRI G. Liver and kidney kynurenine aminotransferase activity in different strains. Adv. Exp. Med. Biol. 467, 629, 1999.
15. BERTAZZO A., PUNZI L., BERTAZZOLO N., PIANON M., POZZUOLI A., COSTA C.V., ALLEGRI G. Tryptophan catabolism in synovial fluid of various arthropathies and its relationship with inflammatory cytokines. Adv. Exp. Med. Biol. 467, 565, 1999.
16. MUELLER P. W., PRICE R., FINN W. New approaches for detecting thresholds of human nephrotoxicity using cadmium as an example. Environ. Health Perspect. 106, 227, 1998.
17. GILES, A.R. Guidelines for the use of animals in biomedical research. Thromb. Haemost 58, 1078, 1987.
18. ZWIERZ K., GINDZIEŃSKI A., GŁOWACKA D., POROWSKI T. The degradation of glycoconjugates in the human gastric mucous membrane. Acta Med. Acad. Sci. Hung. 38, 145, 1981.
19. HOLMES E. W. Determination of serum kynurenine and hepatic tryptophan dioxygenase activity by high liquid chromatography. Anal. Biochem. 172, 518, 1988.
20. HEVERE C., BEYNE P., JAMAULT H., DELACOUX E. Determination of tryptophan and its kynurenine pathway metabolites in human serum by high-performance liquid chromatography with simultaneous ultraviolet and fluorimetric detection. J. Chromatogr. 675, 157, 1996.
21. STONE T. W.. Kynurenic acid antagonist and kynurenine pathway inhibitors. Exp. Opin. Invest. Drugs 10, 633, 2001.
22. CHIARUGI A, MELI E, MORONI F. Similarities and differences in the neuronal death processes activated by 3OH-kynurenine and quinolinic acid. J. Neurochem. 77, 1310, 2001
23. NIWA T, YOSHIZUMI H, EMOTO Y, MIYAZAKI T, HASHIMOTO N, TAKEDA N, TATEMATSU A, MAED K. Accumulation of quinolinic acid in uremic serum and its removal by hemodialysis. Clin. Chem. 37, 159, 1991.
24. KAWASHIMA Y., SANAKA T., SUGINO N., TAKAHASHI M., MIZOGUCHI H. Suppressive effevt of quinolinic acid and hippuric acid on bone marrow erythroid and lymphocyte blast formation in uremia. Adv. Exp. Med. Biol. 223, 69, 1987.
25. GARACIA GE, WIRTZ R A, BARR JR, WOOLFITT A, ROSENBERG R. Xanthurenic acid induced gametogenesis in plasmodium, the malaria parasite. J. Biol. Chem. 273, 12003, 1998.
26. STONE T. W. Neuropharmacology of quinolinic acid and kynurenic acid. Pharmacol. Rev. 45, 309, 1993.
27. MACKENZIE C. R., LANGEN R., TAKIKAWA O., DAUBENER W. Inhibition of indoleamine 2,3-dioxygenase in human macrophages inhibits interferon-gamma-induced bacteriostasis but does not abrogate toxoplasmastasis. Eur. J. Immunol. 29, 3254, 1999.
28. MORONI F. Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Eur. J. Pharm. 375, 887, 1999.
29. WIDNER B., LEBLHUBER F., WALLI J., TILZ G. P., DEMEL U., FUCHS D. Degradation of tryptophan in neurodegenerative disorders. Adv. Exp. Med. Biol. 467, 133, 1999.